home · filing · 0001104659-22-128310
8-K filed December 19, 2022, 6:59 PM ET
ticker TRAW
CIK 0001130598
leadership
confidence high
sentiment positive
materiality 0.35
Onconova adds two independent directors with pharma R&D backgrounds
Traws Pharma, Inc.
Board expanded to eight; elected Peter Atadja (former Novartis Executive Director) and Trafford Clarke (former Eli Lilly Managing Director).
Atadja appointed Chair of Nominating & Corporate Governance; Clarke joins Compensation Committee.
Each receives standard non-employee director compensation plus one-time option to purchase 100,000 shares of common stock.
Atadja led discovery/development of first approved HDAC inhibitor (FARYDAK); Clarke spent 31 years at Eli Lilly in senior R&D roles.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Trafford Clarke
Director
TRAW ·
Traws Pharma, Inc.
Effective 2022-12-19
Filed December 19, 2022, 6:59 PM ET
elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.
Appointed
Peter Atadja
Director
TRAW ·
Traws Pharma, Inc.
Effective 2022-12-19
Filed December 19, 2022, 6:59 PM ET
elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Trafford Clarke was elected as Director at Traws Pharma, Inc..
Action elected
Role Director
Exact text from the filing
elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Atadja was elected as Director at Traws Pharma, Inc..
Action elected
Role Director
Exact text from the filing
elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-22-128310
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.